Factors affecting stability and infectivity of SARS-CoV-2.
High infection rate
Infectivity
Route of transmission
SARS-CoV-2
Stability
Journal
The Journal of hospital infection
ISSN: 1532-2939
Titre abrégé: J Hosp Infect
Pays: England
ID NLM: 8007166
Informations de publication
Date de publication:
Oct 2020
Oct 2020
Historique:
received:
21
04
2020
accepted:
06
07
2020
pubmed:
12
7
2020
medline:
21
10
2020
entrez:
12
7
2020
Statut:
ppublish
Résumé
In late 2019, a novel human coronavirus - severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) - emerged in Wuhan, China. This virus has caused a global pandemic involving more than 200 countries. SARS-CoV-2 is highly adapted to humans and readily transmits from person-to-person. To investigate the infectivity of SARS-CoV-2 under various environmental and pH conditions. The efficacies of various laboratory virus inactivation methods and home disinfectants against SARS-CoV-2 were investigated. The residual virus in dried form or in solution was titrated on to Vero E6 cells on days 0, 1, 3, 5 and 7 after incubation at different temperatures. Viral viability was determined after treatment with various disinfectants and pH solutions at room temperature (20-25 SARS-CoV-2 was able to retain viability for 3-5 days in dried form or 7 days in solution at room temperature. SARS-CoV-2 could be detected under a wide range of pH conditions from pH 4 to pH 11 for several days, and for 1-2 days in stool at room temperature but lost 5 logs of infectivity. A variety of commonly used disinfectants and laboratory inactivation procedures were found to reduce viral viability effectively. This study demonstrated the stability of SARS-CoV-2 on environmental surfaces, and raises the possibility of faecal-oral transmission. Commonly used fixatives, nucleic acid extraction methods and heat inactivation were found to reduce viral infectivity significantly, which could ensure hospital and laboratory safety during the SARS-CoV-2 pandemic.
Sections du résumé
BACKGROUND
BACKGROUND
In late 2019, a novel human coronavirus - severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) - emerged in Wuhan, China. This virus has caused a global pandemic involving more than 200 countries. SARS-CoV-2 is highly adapted to humans and readily transmits from person-to-person.
AIM
OBJECTIVE
To investigate the infectivity of SARS-CoV-2 under various environmental and pH conditions. The efficacies of various laboratory virus inactivation methods and home disinfectants against SARS-CoV-2 were investigated.
METHODS
METHODS
The residual virus in dried form or in solution was titrated on to Vero E6 cells on days 0, 1, 3, 5 and 7 after incubation at different temperatures. Viral viability was determined after treatment with various disinfectants and pH solutions at room temperature (20-25
FINDINGS
RESULTS
SARS-CoV-2 was able to retain viability for 3-5 days in dried form or 7 days in solution at room temperature. SARS-CoV-2 could be detected under a wide range of pH conditions from pH 4 to pH 11 for several days, and for 1-2 days in stool at room temperature but lost 5 logs of infectivity. A variety of commonly used disinfectants and laboratory inactivation procedures were found to reduce viral viability effectively.
CONCLUSION
CONCLUSIONS
This study demonstrated the stability of SARS-CoV-2 on environmental surfaces, and raises the possibility of faecal-oral transmission. Commonly used fixatives, nucleic acid extraction methods and heat inactivation were found to reduce viral infectivity significantly, which could ensure hospital and laboratory safety during the SARS-CoV-2 pandemic.
Identifiants
pubmed: 32652214
pii: S0195-6701(20)30339-X
doi: 10.1016/j.jhin.2020.07.009
pmc: PMC7343644
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
226-231Informations de copyright
Copyright © 2020 The Authors. Published by Elsevier Ltd.. All rights reserved.
Références
Gastroenterology. 2020 Jul;159(1):81-95
pubmed: 32251668
Adv Virol. 2011;2011:734690
pubmed: 22312351
Nat Rev Gastroenterol Hepatol. 2020 May;17(5):259
pubmed: 32214231
Nat Microbiol. 2020 Apr;5(4):536-544
pubmed: 32123347
N Engl J Med. 2020 Apr 16;382(16):1564-1567
pubmed: 32182409
J Virol Methods. 2004 Oct;121(1):85-91
pubmed: 15350737
Lancet. 2003 Apr 19;361(9366):1319-25
pubmed: 12711465
Emerg Microbes Infect. 2020 Dec;9(1):221-236
pubmed: 31987001
J Am Anim Hosp Assoc. 2002 May-Jun;38(3):231-4
pubmed: 12022408
MMWR Morb Mortal Wkly Rep. 2020 May 08;69(18):
pubmed: 32379731
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Lancet Microbe. 2020 May;1(1):e10
pubmed: 32835322
Lancet Microbe. 2020 May;1(1):e14-e23
pubmed: 32835326
Euro Surveill. 2020 Mar;25(10):
pubmed: 32183930